KITE PHARMA INC's ticker is KITE and the CUSIP is 49803L109. A total of 62 filers reported holding KITE PHARMA INC in Q3 2014. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2017 | $2,805,000 | -28.0% | 15,600 | -58.5% | 1.22% | -27.4% |
| Q2 2017 | $3,898,000 | +28.6% | 37,600 | -2.6% | 1.68% | +22.8% |
| Q1 2017 | $3,030,000 | +45.0% | 38,600 | -17.2% | 1.37% | +49.3% |
| Q4 2016 | $2,090,000 | -4.3% | 46,600 | +19.2% | 0.92% | -5.5% |
| Q3 2016 | $2,184,000 | +10.6% | 39,100 | -1.0% | 0.97% | +10.0% |
| Q2 2016 | $1,975,000 | +17.8% | 39,500 | +8.2% | 0.88% | +14.1% |
| Q1 2016 | $1,676,000 | -15.0% | 36,500 | +14.1% | 0.77% | -19.2% |
| Q4 2015 | $1,972,000 | +10.7% | 32,000 | 0.0% | 0.96% | +3.8% |
| Q3 2015 | $1,782,000 | -8.7% | 32,000 | 0.0% | 0.92% | +3.4% |
| Q2 2015 | $1,951,000 | -19.5% | 32,000 | -23.8% | 0.89% | -15.6% |
| Q1 2015 | $2,423,000 | +55.6% | 42,000 | +55.6% | 1.05% | +44.0% |
| Q4 2014 | $1,557,000 | +118.7% | 27,000 | +8.0% | 0.73% | +141.6% |
| Q3 2014 | $712,000 | – | 25,000 | – | 0.30% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Wildcat Capital Management, LLC | 2,410,034 | $433,348,000 | 77.71% |
| COWEN INC. | 4,200,600 | $755,310,000 | 26.72% |
| Tyrus Capital S.A.M. | 1,314,812 | $236,416,000 | 18.49% |
| OMNI PARTNERS LLP | 661,711 | $118,982,000 | 15.19% |
| FNY Partners Fund LP | 379,510 | $68,239,000 | 11.61% |
| EQUITEC PROPRIETARY MARKETS, LLC | 240,100 | $43,172,000 | 10.15% |
| EQUITEC PROPRIETARY MARKETS, LLC | 227,500 | $40,907,000 | 9.62% |
| GARDNER LEWIS ASSET MANAGEMENT L P | 773,817 | $139,140,000 | 8.89% |
| Quad Capital Management Advisors LLC | 192,537 | $34,620,000 | 7.10% |
| Avoro Capital Advisors LLC | 496,983 | $89,363,000 | 6.93% |